Aetna Ozempic Prior Authorization: 3 Verified Policies and 6 Ways In (2026)

Affiliate disclosure: The RX Index may earn a commission from some links on this page. It does not change the coverage rules we report, and it does not change what you pay. Links to providers are labeled.

---

The short answer

Aetna Ozempic prior authorization is not one rule. We could reopen and verify three public Aetna or CVS Caremark policy documents on August 14, 2026 — and they do not work the same way.

One, 4525-H, is a quantity-limit policy with no coverage-criteria section. That does not prove your plan has no prior authorization; it tells you only what that document controls. Another, 5694-D, runs an automatic pharmacy-history check before it asks for paperwork. The third, 2439-C, requires full approval and gives Ozempic six possible coverage paths.

One hard limit before you read further: all three public rulebooks are written for type 2 diabetes. None of them has a weight-loss-only door.

Here's the part that will save you the most time. None of the three public documents says every Ozempic patient must fail metformin. In 2439-C, metformin is one of six doors. In 5694-D, a qualifying metformin fill is one way to pass a history check. In 4525-H, there is no coverage-criteria section at all.

Your own drug list, member portal, approval letter, and plan documents control. Aetna says its public policy pages are only partial descriptions and do not replace the member's benefit plan.

---

Best for you if

• You have type 2 diabetes and your Ozempic prescription got blocked, denied, or is stuck "pending"
• Your approval is expiring and you need to renew it
• You got a denial letter that doesn't explain what went wrong
• You want to know exactly what your doctor's office needs to send

Not for you if

• You want Ozempic for weight loss only. Skip to Will Aetna cover Ozempic for weight loss? and we'll point you somewhere useful.
• You have Aetna Medicare or Aetna Better Health (Medicaid). Different rules entirely. We cover both further down, briefly, then hand you off.

---

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

---

Three verified Aetna/Caremark Ozempic rulebooks, side by side

This table is why this page exists. It separates what each public document actually says from what your exact plan may still require.

Where each one lives, and how current it is — because you deserve to know how fresh our sources are:

• 2439-C — Aetna's own 2026 page, dated March 18, 2026, plus the matching CVS Caremark PDF.
• 5694-D — CVS Caremark's public PDF, marked P05-2025 and copyright 2025.
• 4525-H — Aetna's own site, in its 2024 non-Medicare folder. Page dated October 27, 2024.

We're telling you those dates on purpose. Two documents are older than the newest Ozempic tablet. We didn't hide that behind a confident-sounding summary, and you shouldn't trust a page that does.

We also found references to policy 5496-C, but we could not reopen a current public primary-source copy on August 14, 2026. We left it out rather than ask you to trust a rule we could not independently recheck.

---

The one thing we can't tell you

We can't tell you whether your plan uses one of these three public documents, or which one.

Aetna's public website can't do that from a generic page. Your member-level drug list and plan documents can. Your employer or plan sponsor may choose the benefit design, and the exact choice is not shown in these public policy pages.

So we did the next best thing: we published all three documents we could reopen, in plain English, with the exact history check, refill math, and criteria. Then we built a short screen that narrows down which public path you should check first.

➜ Find which public Aetna path fits your situation — 6 questions, no email, no personal info It is a read-it-yourself screen. You do not enter or submit anything.

The 6-question Aetna Ozempic rulebook finder

Answer these in order. This does not tell you that you qualify. It tells you which public path is worth checking against your member-level rules.

1. Does your own drug list show PA next to Ozempic? If no, check for a quantity-limit marker and ask the pharmacy to run the claim. If yes or you do not know, keep going.
2. Did the rejected claim include a true type 2 diabetes diagnosis code? Under 5694-D, that can pass the automatic check.
3. In the last 730 days under the same CVS Caremark benefit, did you fill a qualifying diabetes supply, metformin, or another diabetes drug outside the target list? The timing rules are different for each route; use the exact breakdown below.
4. Have you been on a steady maintenance dose of a covered GLP-1 or GIP/GLP-1 drug for at least three months? That separates a new request from a continuation request under 2439-C.
5. Was the request for the Ozempic pen or Ozempic tablet? The condition-based doors are different.
6. Which real item in your medical record matches the policy: a metformin problem, combination therapy with A1C 7.5% or higher, MASLD/MASH, established heart disease, chronic kidney disease, or high cardiovascular risk?

Bring those six answers to your doctor's office or Aetna. Do not ask anyone to change a diagnosis to fit a rule. The goal is to find the door your real record already supports.

---

The right GLP-1 path isn't the same for everyone

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Compounded semaglutide is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Do not treat compounded semaglutide as generic Ozempic or as the same product.

That said — if you're here because a prescription got blocked, finish this page first. The paperwork fix is usually cheaper than switching.

---

What we actually verified

Checked August 14, 2026. We opened and read, end to end:

• Aetna policy 2439-C, on Aetna's own site, page dated March 18, 2026
• The matching CVS Caremark 2439-C PDF
• CVS Caremark policy 5694-D
• Aetna policy 4525-H, on Aetna's own site, page dated October 27, 2024
• The live 2026 Aetna Standard Plan Pharmacy Drug Guide, retrieved August 14, 2026; the Ozempic and antiobesity pages we used are dated August 1, 2026
• Aetna's current pharmacy coverage FAQ and commercial submission routes
• FDA's January 30, 2026 Ozempic tablet approval letter and the current prescribing information
• Aetna's Medicare GLP-1 Bridge page, updated August 10, 2026
• CMS's Medicare GLP-1 Bridge page
• CVS Caremark's 2025 annual utilization review report filed with the State of Indiana
• Novo Nordisk's current Ozempic price guide and savings-program terms
• Ro's live insurance-checker, pricing, insurance-support, and Ozempic pages

Every percentage on this page is our own calculation from the raw counts in Caremark's Indiana filing. We show the counts and the denominator so you can check our math.

What we did not verify: your plan, your formulary, your medical record, or whether you'll be approved. We also could not confirm a current public copy of 5496-C. We tell you the date or version of every policy copy we did use.

---

Does Aetna require prior authorization for Ozempic in 2026?

Sometimes. Your member-level drug list decides. The three public documents we could verify disagree about the process. One has no coverage-criteria section — only refill limits. Another pays the claim under its automatic screen if your diagnosis code or pharmacy history fits. The third requires full approval. Which one applies depends on the plan you have.

(A pharmacy benefit manager, or PBM, is the company that runs the drug side of your insurance. CVS Caremark administers pharmacy benefits for many Aetna plans — which is why you'll see both names on the same rules.)

Let's walk through them, easiest to hardest.

4525-H: the quantity-limit policy

This document is short. It lists the drugs, lists what the FDA approved each one for, gives a table of refill limits, and ends.

There is no coverage-criteria section. No diagnostic test. No metformin rule. No approval length.

That does not prove your exact plan has no prior authorization. Aetna says its public policy pages are partial descriptions and the member's benefit plan controls. The accurate conclusion is narrower: 4525-H itself is a quantity-limit policy, not a PA-criteria policy.

One honest note: this page is dated October 27, 2024. It predates Ozempic tablets and does not include them. Aetna still publishes it in its public 2024 non-Medicare folder.

5694-D: the one that checks your history first

This one runs an automatic check before any paperwork happens. Aetna's document calls it "screen out logic." If you pass the check, the claim passes that PA screen. If you fail it, then a prior authorization is required.

We break the check down in the next section, because it's the single most useful thing on this page.

Two details worth flagging now. First, if you do end up needing approval under 5694-D, the public document asks you to prove type 2 diabetes one of four ways. It does not add the six-door test used in 2439-C. Second, approval under 5694-D lasts 36 months.

This public copy predates the Ozempic tablet name. It lists Ozempic as a target drug, but it does not give tablet-specific criteria or quantity limits. For a tablet claim, confirm the policy number on your own case before relying on 5694-D.

2439-C: the strict one

This is the newest dated public Aetna page in the set we verified, and it's the toughest of the three. Three separate gates, and the third one is where the metformin option lives. Full breakdown further down.

If you only had one public policy to prepare around, prepare for 2439-C. That does not override your own plan, but it gives your doctor's office the fullest record packet.

---

What people are actually asking

You're not the only one confused. Here's how real people describe this on Reddit, in their own words:

"Curious what conditions they cover." — Aetna prior-authorization thread

"Are the people getting coverage … just getting lucky?" — coverage thread

"My Dr didn't send enough evidence." — prior-authorization denial thread

That last one is the whole game, and we'll show you exactly how to reduce that risk.

We use these to show what people are trying to figure out. We don't use forum posts as evidence for what any plan actually requires — for that, we only use the plans' own documents.

---

The 730-day rule that can skip the prior authorization under 5694-D

Under policy 5694-D, your pharmacy claim runs through an automatic check before any paperwork starts. If the claim carries a true type 2 diabetes diagnosis code, it passes that screen. If it doesn't, the system looks back 730 days under the same CVS Caremark benefit for certain diabetes fills. Only if every screen fails does the claim reject for prior authorization.

Read that again, because it's worth money.

Four ways in, and you only need one

The diagnosis-code route is not permission to change a diagnosis. It applies only when type 2 diabetes is true, documented, and correctly carried on the claim.

The extra metformin timing rule

A metformin fill does not count just because it happened sometime in the last two years. The public policy also says it must be at least 10 days before the Ozempic claim.

That means a same-day metformin fill and Ozempic claim may still fail the screen. The dates matter.

Which supplies count — and which ones don't

The policy excludes insulin pen needles and insulin syringes by name. It does not publish a complete brand list or NDC list for everything that counts.

We cross-checked Aetna's current Standard Plan guide because it lists many covered diabetes supplies. But a formulary listing is not the same thing as the 5694-D screen-out list, so we will not turn that cross-check into a false yes-or-no table.

So a box of test strips from twenty-two months ago may help if it was processed as a qualifying 30-day diabetes-supply fill. A box of pen needles from last week can't.

The trap: your own Ozempic doesn't count

The policy excludes what it calls the "target drugs." That list includes Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, Byetta, and Bydureon BCise.

Your own past Ozempic fills do not help you here. Neither does a year on Trulicity. Metformin may. A DPP-4 inhibitor or insulin may. The exact claim still has to meet the public screen and your benefit rules.

This is not step therapy — and the difference matters

We see these two blurred constantly, and it leads people to the wrong fix.

• Step therapy = "try a different drug first before we'll cover this one." That's a rule about what the plan requires.
• This auto-check = "if your claim history already looks like diabetes treatment, this PA screen can clear." That's a rule about what is already in the record.

If a pharmacist tells you "step therapy," ask which prerequisite and exception rule applies. If the claim rejected because the 5694-D history screen failed, ask which diagnosis or history item was missing. Different problems, different paperwork.

How to check yourself in about a minute

1. Open your pharmacy app or CVS Caremark account.
2. Look at prescription and supply fills going back 730 days under the same benefit.
3. Look for a non-target diabetes drug.
4. If you find metformin, make sure the fill was at least 10 days before the Ozempic claim.
5. If you find a diabetes supply, check whether it represented at least a 30-day supply and was not pen needles or syringes.
6. Give the exact fill date and claim details to your doctor's office or Caremark. Ask whether the pharmacy should rerun the claim before anyone starts a new form.

➜ Get the free one-page sheet to hand your doctor's office The exact public rule, the four routes, and a checkbox for the one that fits your real record. No email required.

---

What Aetna's Ozempic prior authorization actually requires

Under 2439-C, the full public PA rulebook, you clear three gates: you must be in the right request lane, you must document type 2 diabetes one of four ways, and you must fit one of six doors. Under 5694-D, that third gate does not appear. Aetna doesn't use the word "gates" — that's our plain-English way of organizing what the policy actually says.

Gate 1: are you starting, or continuing?

The very first line of the criteria asks whether you have not been on a steady maintenance dose of any covered GLP-1 or GIP/GLP-1 drug for at least three months.

That sounds like a technicality. It isn't. It decides which criteria your doctor uses.

• Never been on one of the covered drugs, or been on one under three months? New request.
• Been on a steady dose three months or more? Continuation request. Different criteria.

This is a preventable denial path hiding on line one. If you've been on Trulicity for two years and the request is handled only as a new start, the public new-request criteria do not fit your history. Not because you don't qualify. Because the wrong lane was used.

Gate 2: prove the diabetes, four ways

You need one of these four, and the policy marks every single one as requiring documentation:

Two details most pages get wrong:

It says "a history of." Not "your most recent." The public text does not set an age limit on the qualifying result. An older documented result may fit the wording, but your member-level plan and reviewer still control.

The fasting-glucose option has the extra hoop. It is the only one with a second condition attached — the record has to show the patient fasted for at least eight hours. If your office is submitting fasting glucose, put the fast in the record, not just the number.

Gate 3: the six doors

This is where the metformin option lives — and where most people find out they had another way in.

Under 2439-C, you need one of these. Note which ones depend on which Ozempic you were prescribed:

(MASLD and MASH are the newer names for forms of fatty liver disease. Aetna lists these as compendial uses — uses backed by recognized drug references rather than the Ozempic FDA label. They still count as policy doors. They are not FDA approvals, and we won't call them that.)

The Ozempic pen's kidney door has no numeric threshold

Look at that kidney row again.

The Ozempic pen needs only "a diagnosis of chronic kidney disease." The public wording gives no eGFR threshold.

Compare that to Trulicity and Victoza in the same document. Their kidney door requires advanced kidney disease, with an eGFR under 30.

The Ozempic pen is the only drug in this policy with a kidney door that has no numeric threshold attached. If you have a real, documented CKD diagnosis and you were prescribed the pen, that is a door in the public policy — and metformin does not have to be your door.

How Ozempic compares to the other drugs in the same policy

Since one document covers seven drugs, here's how many distinct doors each one gets:

Ozempic and Trulicity are tied at the top. Mounjaro gets three — metformin, combination therapy with A1C 7.5% or higher, and MASLD/MASH. It does not get a product-specific heart or kidney door in 2439-C. If your doctor is choosing between covered options and formulary access matters, that's a real difference in the same document.

---

Do you have to try metformin before Aetna covers Ozempic?

Not as a universal rule in any of the three public documents we verified. Metformin appears as one door in 2439-C, and even there it is not mandatory if another door fits. In 5694-D, a properly timed metformin fill is one way to pass a history screen. Your specific plan can still add its own separate step-therapy rule, which is different from these public criteria.

This myth can send people down the wrong path.

Where the myth comes from

2439-C puts the metformin option first. Skim it and you'll write "Aetna requires metformin." We understand how it happened. It's still wrong, in two ways:

1. 4525-H has no coverage-criteria section, and 5694-D uses metformin only as one history-screen route.
2. Even in 2439-C it is one of six. It sits first in a list where you only need one matching door.

We also found pages claiming Aetna's Ozempic rule requires "one month of metformin," a BMI of 30, a 6-month lifestyle program, or a minimum age of 18. None of those appears anywhere in 2439-C. We read it top to bottom.

If metformin IS your door, document it properly

"Patient tried metformin" is thin documentation. Aetna's policy accepts three different metformin situations, and the record should make the matching one clear:

But check the other five doors first

Before your office writes anything about metformin, run this list:

1. Are you adding Ozempic to another diabetes drug, and is your A1C 7.5% or higher?
2. Do you have MASLD or MASH on your chart?
3. Do you have established heart disease, and were you prescribed the pen?
4. Do you have a chronic kidney disease diagnosis, and were you prescribed the pen?
5. Are you at high risk of a major heart event, and were you prescribed the tablet?

Any yes, and metformin does not have to be the door used under 2439-C.

One important line, and we mean it: the goal is to find the door that matches your real medical record — not the one that sounds easiest. Never ask a doctor to shade a diagnosis to fit a coverage rule. Aside from being wrong, it tends to unravel at the worst possible moment.

---

Are the rules different for Ozempic tablets and the Ozempic pen?

Yes, and this is new. FDA approved the name change to Ozempic tablets on January 30, 2026. Rybelsus still exists. Aetna's policy gives the pen a heart-disease door and a kidney door that the tablet doesn't get, and gives the tablet a high-heart-risk door the pen doesn't get. Refill limits differ too.

There are now two Ozempic dosage forms

If your doctor said "Ozempic," ask which one. It changes your paperwork.

• Ozempic pen — once-weekly injection. The marketed pens deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg doses; the pens contain 2 mg, 4 mg, or 8 mg per 3 mL.
• Ozempic tablet — once-daily pill in 1.5 mg, 4 mg, and 9 mg. The 1.5 mg dose is the starting dose and is not a maintenance dose for glucose control.

If you were on Rybelsus, do not assume a milligram-for-milligram swap. The products are not substitutable milligram for milligram. After the 30-day start phase, the current prescribing information describes a switch from Rybelsus 7 mg to Ozempic tablet 4 mg, or Rybelsus 14 mg to Ozempic tablet 9 mg. It does not give a direct Rybelsus 3 mg-to-Ozempic 1.5 mg conversion. Your prescriber controls the switch.

Why the doors are different — and it's not random

The product-specific doors track the FDA labels.

The pen is FDA-approved to lower the risk of major heart events in adults with type 2 diabetes and established heart disease, and to reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease. So Aetna gives the pen a heart-disease door and a kidney door.

The tablet is FDA-approved to lower the risk of major heart events in adults with type 2 diabetes who are at high risk for those events. So Aetna gives the tablet a high-risk door instead.

Once you see it, the whole thing stops feeling arbitrary. Aetna is tracking two different labels for two dosage forms with the same brand name.

One paperwork warning

Some offices are still working from materials that predate the 2026 tablet name. If the request doesn't clearly say pen or tablet, the reviewer may check it against the wrong product-specific door — and the denial letter may say only "criteria not met."

Make sure the request names the exact product. It's a five-second check that can prevent a needless delay.

---

Will Aetna cover Ozempic for weight loss?

Not through the three public Ozempic policies we verified. Ozempic is not FDA-approved for weight loss. Aetna's current Standard Plan guide lists both the Ozempic pen and Ozempic tablets under diabetes drugs, not under antiobesity drugs. None of the three public Ozempic documents gives weight loss its own door. Your exact plan still controls any exception right.

We're being blunt because being gentle here costs you a month.

The proof, from Aetna's own current formulary

We pulled Aetna's live 2026 Standard Plan drug guide and looked at both categories. The Ozempic and antiobesity pages we used are dated August 1, 2026.

Under "Antidiabetics, Incretin Mimetic Agents," Aetna lists the Ozempic pen, Ozempic tablets, and Rybelsus. All three are marked preferred brand in this Standard Plan guide.

Under "Antiobesity," Aetna lists products made and labeled for weight management, including Foundayo, Wegovy injections and tablets, Saxenda, and Zepbound forms. Ozempic is not in that category.

Both Ozempic dosage forms are in the diabetes category, not the antiobesity category. That's not our opinion. That's where Aetna's own current Standard Plan puts them.

The useful split we found across Aetna's own documents

The August Standard Plan guide and 2439-C now line up on one important point: both include the Ozempic pen and Ozempic tablets. The guide marks both dosage forms PB — preferred brand — and 2439-C gives each form its own criteria and quantity limits.

But that still does not mean every Aetna plan covers both forms. A public formulary shows one plan design, and a public PA policy explains criteria; your member-level drug list controls your benefit.

The same Standard Plan guide marks Victoza NF, non-formulary, while 2439-C still contains clinical criteria for Victoza. That is the clean proof that a PA policy and a formulary are different documents doing different jobs.

What diagnosis wording can do

We found three published Massachusetts Medicaid appeal decisions where Ozempic was denied, and the listed reason for use was weight gain or obesity:

In the third case, the appellant asked the hearing officer to consider "the spirit of the law." The appeal was still denied.

These are historical Massachusetts Medicaid cases, not Aetna cases. Different program, different rules. We include them only to show why the stated diagnosis and covered indication matter. They do not predict what Aetna will do in your case.

Where to go instead

If weight loss is why you're here, stop reading this page. Seriously — the diabetes paperwork below is not your path.

Wegovy is the semaglutide brand FDA-approved for chronic weight management, and Aetna's current Standard Plan lists Wegovy products in the antiobesity category. Its prior-authorization rules are separate.

➜ See Aetna's separate Wegovy prior-authorization rules

---

What does my doctor need to send with the Aetna Ozempic prior authorization?

For a 2439-C request, the packet has to make two things obvious: the documented result that supports type 2 diabetes, and which specific door you're using. For a 5694-D request after the history screen fails, the public document asks for the type 2 diabetes proof but does not add the six-door test. Aetna's criteria mark every diagnostic option as requiring documentation. Make the actual value and date visible in the submitted record — not just mentioned in a message.

The safest core packet

• The exact product: Ozempic pen or Ozempic tablet, with the strength
• Type 2 diabetes diagnosis
• One qualifying result, with the value and date
• If 2439-C applies, which door you're using, named plainly
• The record that supports that door
• If 2439-C applies, whether this is a new request or a continuation
• Your member ID and the exact plan information the office uses to submit

What each door needs on top

The five-second check that catches preventable problems

Before the office hits send:

1. Does it name pen or tablet?
2. Is the qualifying value visible, with a date — not just referenced?
3. Is the door named, not implied?
4. Is the supporting record included, not merely summarized in a portal message?
5. Is it filed as new or continuation, correctly?

That's it. Those five things are, in our reading of the public policy, where several preventable problems can start.

One-page prescriber sheet

Copy or print this block. Check only what is true in the patient's real record.

• [ ] Exact request: Ozempic pen / Ozempic tablet
• [ ] New request / continuation after at least three months on a steady dose
• [ ] Type 2 diabetes documentation: A1C 6.5%+ / 2-hour OGTT 200+ / symptoms or crisis with random glucose 200+ / fasting glucose 126+ after at least eight hours fasting
• [ ] 2439-C door: metformin issue / combination therapy with A1C 7.5%+ / MASLD or MASH / established cardiovascular disease with pen / CKD with pen / high cardiovascular risk with tablet
• [ ] Supporting value, date, diagnosis, and record are visible
• [ ] Case or reference number requested after submission
• [ ] If checking 5694-D first: true type 2 diabetes claim code / qualifying 30-day diabetes supply / metformin at least 10 days before claim / another non-target diabetes drug in last 730 days

Copy this and send it to your doctor's office

You don't need to be pushy. You need to be specific. Here's a message you can paste into a patient portal:

Hi — I'd like to check on the Ozempic prior authorization. Could you confirm the request included my qualifying lab result with the date, named which coverage criterion we're using, and specified whether it's Ozempic pen or Ozempic tablet? Also, is this filed as a new request or a continuation? If you can send me the case number, I'll track it on my end. Thank you.

That message does four things at once: it's polite, it's specific, it makes the office check the exact items that can sink a request, and it gets you a case number so you can trace the request if it stalls.

➜ Jump back to the one-page prescriber sheet

---

Which Aetna Ozempic prior authorization form should my doctor use?

There isn't one universal Ozempic form to download. Aetna says you or your pharmacy can ask your doctor to start prior authorization. The doctor can then submit through CoverMyMeds, by phone, or by fax. A current Aetna drug guide also gives a mail route. Medicare and Medicaid plans use different routes. Searching for a generic "Aetna Ozempic PA form" PDF is one of the fastest ways to send a request to the wrong place.

This trips up a lot of people, because searching for a form feels like the obvious first step.

Why a random PDF is risky

• Commercial, Medicare, and Medicaid can run different processes
• State Medicaid plans publish their own separate forms
• Old versions stay indexed on the internet for years
• The correct request is often generated after the exact plan is entered electronically

The channels Aetna publishes for commercial plans

These are for the prescriber's office, and we confirmed them in Aetna's current pharmacy FAQ and live 2026 Standard Plan guide:

Ozempic is handled through the nonspecialty route in Aetna's guide. Your member ID card or plan instructions win if they give a different route.

Six steps so the request doesn't vanish

1. The office submits under your exact plan
2. Get the case or reference number
3. Write down the date and how it was sent
4. Confirm which records were included
5. Ask whether anything is still missing
6. Check your member portal, and keep the decision letter

Step 2 is the one people skip, and it's the one that matters. Without a case number, "we sent it" is unverifiable.

---

How long does Aetna take to approve an Ozempic prior authorization?

Aetna does not publish one universal commercial Ozempic turnaround time. The best drug-level public dataset we found is CVS Caremark's 2025 annual report filed with Indiana. In that one report, the average from submission to decision across 35,097 initial requests was 0.27 days, about six and a half hours. Ozempic specifically averaged 0.15 days — about three and a half hours across 423 requests.

That is fast. It is also one state report from one year, not a promise for your case.

What a fast answer does — and does not — tell you

In the same Indiana data, 244 of 423 Ozempic requests were denied — 57.7%.

Those two facts sit next to each other. But the report does not say which requests were fully automated, which reached a person, what records were missing, or why one request took longer than another.

So if you got a denial back the same afternoon, don't assume the speed proves the case was careful, careless, automated, or final. Timing alone cannot tell you. The useful question is still: which exact criterion or record was missing?

What to track instead of guessing

• Date submitted
• Case number
• How it was sent
• Current status
• Exactly what's missing, if anything
• When the office has to respond by

When "pending" really means "waiting on your doctor"

This is the stall these four questions are built to break:

1. Has Aetna received the request?
2. Is it complete?
3. Did Aetna send my office a question, and on what date?
4. When does the case close if nobody responds?

Question 4 is the one that gets things moving.

A note on urgency: don't claim a request is urgent just to speed it up. An expedited review is for cases where the plan's rule and the clinician's judgment support urgency. That's a clinical call your doctor makes, not a box you invent.

---

Aetna denied my Ozempic prior authorization. Now what?

First, figure out whether you were actually denied or the case was incomplete — those need different responses. Your letter may not tell you which criterion failed. In CVS Caremark's 2025 Indiana filing, all 14,114 reported denials across all drugs were placed under one reason: "does not meet clinical criteria." One broad label, for everything in that report.

That's why a letter can feel vague. Call the number on it and ask for the policy number and the exact criterion used.

The numbers that should change what you do next

From that same Indiana, all-drug filing, and these are our calculations from the raw counts:

Sit with that gap.

In this one dataset, one in ten denied requests was appealed. Almost six in ten filed appeals were approved.

That is not an Ozempic-only success rate, and it is not a national Aetna promise. It is still strong evidence that a denial is not always the end of the road.

Decode your denial before you appeal

Appealing blindly wastes the fastest fix. Find your denial language in this table first:

Fix it, or appeal it?

Fix and resubmit when:

• A required result wasn't included
• The metformin history had no useful detail
• A supporting record was mentioned but not provided
• The wrong product (pen vs. tablet) or wrong lane (new vs. continuation) was used

Appeal when:

• The record was complete and you disagree with the reading
• The plan is interpreting its own rule differently than the document says
• The drug is off-formulary but an exception path exists

What goes in the appeal

• The denial letter and case number
• The exact reason given
• The policy number and the criterion that matches your real record
• The records that were missing or misunderstood
• A short note from your prescriber correcting any factual mistake

Deadline: follow the deadline and instructions in your denial letter. That letter controls. Aetna's public pharmacy FAQ says a coverage-exception appeal can take up to 15 business days to process, and a second-level appeal, when the plan allows one, can also take up to 15 business days.

After internal appeals are exhausted, some cases may qualify for an independent external review under plan terms and applicable law.

Copyable appeal letter template

Subject: Appeal of Ozempic coverage denial — case [CASE NUMBER] I am appealing the denial dated [DATE] for [OZEMPIC PEN / OZEMPIC TABLET]. The denial states: [EXACT REASON]. The request is for treatment of documented type 2 diabetes. The policy used was [POLICY NUMBER, IF KNOWN]. My record supports the following criterion: [NAME THE LAB-HISTORY ROUTE] and [NAME THE 2439-C DOOR, IF THAT POLICY APPLIES]. The attached records show: [VALUE AND DATE], [DIAGNOSIS OR TREATMENT HISTORY], and [OTHER SUPPORTING RECORD]. Please review the request using the correct product and [NEW / CONTINUATION] criteria. Please send the written decision and identify any remaining missing item or criterion.

➜ Copy the appeal template and fill in only the facts your records support

---

What does Aetna require to renew Ozempic?

Renewal isn't just the same rules again. Under 2439-C, continuation flips the first gate — you now must have been on a steady dose for at least three months — drops two initial doors, and adds an A1C-reduction door. Approval under 2439-C runs 12 months; approval under 5694-D runs 36 months.

What changes between your first approval and your renewal

The renewal bar is softer than people expect

That new door says the patient has shown a reduction in A1C since starting the covered therapy.

The policy puts no number on it. Not 1%. Not 0.5%. Just a reduction.

In practical terms, renewal may come down to having a follow-up A1C on file that's lower than where you started. If you're due for renewal and haven't had labs in a while, ask your clinician what monitoring is due.

Renewal checklist

• Your original qualifying result
• Proof you've been on a steady dose for three months or more
• A follow-up A1C showing a reduction, if that is the continuation door used
• Updated records if you're using a condition-based door instead
• The exact product — pen or tablet

Don't wait for the expiration

Aetna's public FAQ says that when a prior authorization expires, the doctor needs to submit a new request if treatment should continue. A pharmacy claim may reject while the new request is unresolved.

Our suggestion — and these are our reminders, not Aetna deadlines — is to start at 60 days out, follow up at 30, and escalate at 14.

---

Why does my pharmacy say it's too soon to refill my Ozempic?

Because the public quantity-limit policies use shorter processing periods than the supply they represent. For the pen, 2439-C and 4525-H use one pen per 21 days for a 28-day fill. For the tablets, 2439-C uses 30 tablets per 25 days for a 30-day fill. The documents say those shorter periods allow time for refill processing.

Do the math and you get something useful.

That does not guarantee every pharmacy can process the claim exactly on day 21 or day 25. Your plan, last paid claim, package size, and pharmacy billing still control. It tells you the public policy's published quantity-limit timing.

If the pharmacy says too soon, count from the last paid fill date. If the policy period has not passed, the rejection may be working as written. If it has passed, ask the pharmacy to check the billed day supply, package size, last paid claim, and authorization dates.

These limits match in 4525-H and 2439-C for the pen. 5694-D does not publish an Ozempic quantity table, so we will not pretend all three documents agree on a limit they do not all state.

---

What does Ozempic cost with Aetna after the prior authorization is approved?

Approval and price are two separate questions. Getting approved means your plan will cover it under its terms. What you pay still depends on your tier, deductible, coinsurance, and pharmacy. If you have eligible commercial insurance with Ozempic coverage for an FDA-approved indication, Novo Nordisk's savings offer can bring the price to as little as $25 — but the savings are capped at $100 per one-month fill, which is the detail that decides whether $25 is real for you.

The $25 headline, and the cap under it

Here's the arithmetic almost nobody publishes:

• The offer pays up to $100 toward a one-month fill, up to $200 for two months, or $300 for three
• You pay a minimum of $25
• So $25 happens only when the amount left after insurance is $125 or less

If the eligible amount left after insurance is $200, the $100 cap leaves $100. If it's $400, the cap leaves $300.

The offer is genuinely good. It's just capped, and the cap is what determines your number. Activation can remain valid for up to 48 months, subject to current terms. Medicare, Medicaid, VA, DOD, and TRICARE beneficiaries are excluded from the commercial copay offer. FEHB, ACA Marketplace plans, and state employee plans are not treated as government programs for this offer.

If Aetna won't cover it

Novo Nordisk publishes manufacturer self-pay prices for the same brand-name Ozempic products:

Note the dose limit and expiration date. The $199 intro price is for patients who meet Novo Nordisk's current definition of new to the offer, and it applies only to the first two monthly fills of the 0.25/0.5 mg pen through December 31, 2026.

The honest order of cheapest to most expensive

We're going to say something against our own interest here, because it's true:

1. Approved Aetna coverage plus the savings offer — often the cheapest route when you are eligible
2. Fix an incomplete request or use a valid appeal right — use the plan's review process before paying cash
3. Buy direct from the manufacturer — $149 to $499 depending on product and dose
4. Cash-pay telehealth — add the membership fee and medication price before comparing

We earn nothing on the first three. We're still telling you to work through them in that order, because that's the order most likely to keep added costs down.

For the full breakdown of the savings offer, including enrollment steps and what to do if it gets rejected at the counter, see our dedicated page: Ozempic Savings Card: eligibility, the real cost, and rejection fixes

---

Does Aetna Medicare use the same Ozempic prior authorization rules?

No. Aetna's policy pages above are labeled non-Medicare, and none of these public rules should be assumed to govern a Part D plan. Aetna Medicare runs on Part D drug lists with their own criteria. And on one point Aetna is unusually direct: the Medicare GLP-1 Bridge program does not cover Ozempic.

The Bridge confusion, settled

We've watched a lot of pages get this wrong, so here it is from Aetna's own Medicare page, updated August 10, 2026:

"No. Ozempic isn't part of the Medicare GLP-1 Bridge program."

Aetna adds that Ozempic may still be covered under your Part D plan when it's prescribed for type 2 diabetes, depending on your plan's drug list.

Here's what the Bridge actually is, so you can stop wondering:

And one line that saves a phone call: Aetna Medicare does not approve Bridge requests. Those go to CMS. Calling Aetna to approve the Bridge is a dead end by design.

If you have Aetna Medicare and type 2 diabetes, the Bridge is not your Ozempic path. Your path is your Part D drug list, and Aetna's own page says as much.

➜ See Aetna Medicare GLP-1 coverage rules in full

---

Does Aetna Better Health use the same Ozempic criteria?

No, and we're not going to pretend there's a national answer. Aetna Better Health runs through state Medicaid programs. Each state sets its own preferred drug list, its own criteria, its own forms, and its own submission phone and fax numbers. A rule that's true in Texas may be wrong in Maryland.

Don't apply anything from the commercial section above to a Medicaid plan. Start with your state's current preferred drug list and its own prior authorization page.

If you can't find your state's current rule, call the number on your member ID card. That's a better answer than a national generalization, and we'd rather send you there than publish something that's stale in your state.

---

What if you don't have an Aetna path to Ozempic?

This section is for a specific reader: your plan excludes it, your appeal failed, or you don't have a clinician actively managing your diabetes and need one. If Aetna covers your Ozempic and your own clinician is managing your care, skip this — telehealth would cost you more for less.

Still here? Then the useful thing is knowing what's actually free versus what costs money.

Start with the free coverage check

Ro publishes a free GLP-1 Insurance Coverage Checker. You enter your name, insurance-card information, and relevant eligibility details. Ro says an insurance specialist contacts your insurer and emails a personalized coverage report for the Ozempic pen, Wegovy pen, and Zepbound pen.

It's free and it does not submit a treatment request or write a prescription. It is not instant, and it is not anonymous. For someone who's been getting vague answers, a plan-specific report can still be a real step forward.

The honest limitation

Ro's free checker covers the Ozempic pen, not the Ozempic tablet. It also does not currently check the Wegovy pill, Foundayo pill, or Zepbound KwikPen.

If the Ozempic tablet is what you were prescribed, this checker will not answer your question. Use your Aetna member portal, the drug-pricing tool, or the number on your member ID card instead.

➜ Check your Ozempic pen coverage free with Ro's insurance checker (affiliate link) This produces a coverage report after Ro contacts the insurer. It is not a prescription, a treatment request, or a guarantee of coverage. It requires personal and insurance information.

Provider-stated versus verified, as of August 14, 2026

If you want someone to handle the paperwork

Ro Body is Ro's paid weight-management program. If you're clinically eligible, it includes an insurance concierge that coordinates prior-authorization paperwork for supported medicines. Verified pricing as of August 14, 2026:

Get started for $39, then as low as $74/month with the annual plan paid upfront.

Two things we won't blur, because other sites do:

• The free checker and the paid membership are different things. One is a report. One is a program.
• Neither guarantees coverage. Nobody can promise that. If a page tells you a service will "get your Ozempic approved," close the tab.

One more distinction that matters for this page specifically: Ro Body is a weight-management program, and Ro says affiliated providers may prescribe Ozempic off-label for weight loss when appropriate. That is exactly the use the public Aetna Ozempic policies do not give a weight-loss-only door. If your goal is diabetes coverage, start with the clinician managing your diabetes. Ro's useful role here is the free pen coverage report or paid paperwork support — not a promise that Aetna will cover off-label use.

➜ See Ro Body's current pricing and insurance support (affiliate link) Membership and medication are billed separately. Coverage is not guaranteed.

Everything on this page still works if you ignore both of those links. That's the test we hold ourselves to.

---

How we built this page

We're an independent GLP-1 decision resource, not an insurance company and not a medical practice. This page exists because Aetna publishes Ozempic rules across several documents that do not say the same thing, and a member's own plan can add another layer.

What we did: opened the three public Aetna and CVS Caremark policy documents we could independently reopen and read them start to finish, pulled Aetna's live 2026 Standard Plan drug guide, read Aetna's current pharmacy FAQ and Medicare Bridge page, checked FDA's Ozempic tablet approval letter and prescribing information, and calculated appeal percentages from the raw counts in CVS Caremark's 2025 Indiana filing.

What we deliberately did not publish, and why — because what a page refuses to say tells you as much as what it says:

One technical note for anyone checking our work. Aetna's HTML version of 2439-C visually nests the six doors under the fasting-glucose line. The matching Caremark PDF shows them as a separate requirement. We used the PDF structure.

Corrections: If a policy has changed or a source has moved, tell us and we'll update within 48 hours.

Byline: The RX Index Research Team. No medical reviewer — because we don't have one, and inventing one would be worse than admitting it. This page reports coverage rules. It is not medical advice, and whether Ozempic is right for you is a conversation between you and your clinician.

Primary sources

1. Aetna policy 2439-C, dated March 18, 2026
2. CVS Caremark 2439-C PDF
3. CVS Caremark 5694-D PDF
4. Aetna policy 4525-H, dated October 27, 2024
5. Aetna Standard Plan 2026 Pharmacy Drug Guide
6. Aetna pharmacy coverage FAQ
7. FDA Ozempic tablet approval letter, January 30, 2026
8. Ozempic tablets prescribing information
9. FDA: concerns with unapproved GLP-1 drugs
10. CVS Caremark 2025 Indiana annual utilization review report
11. NovoCare Ozempic price guide, May 2026
12. Novo Nordisk diabetes savings-offer terms
13. Aetna Medicare GLP-1 Bridge page
14. CMS Medicare GLP-1 Bridge
15. Ro GLP-1 Insurance Coverage Checker
16. Ro Body pricing
17. Ro insurance support
18. Ro Ozempic page
19. MassHealth appeal 2301586
20. MassHealth appeal 2301244
21. MassHealth appeal 2307991

---

Frequently asked questions

Does every Aetna plan require prior authorization for Ozempic? No. Your member-level drug list controls. Of the three public documents we could reopen, 4525-H has quantity limits but no PA-criteria section, 5694-D uses an automatic history screen before PA, and 2439-C has full clinical criteria. The absence of criteria in 4525-H does not prove your exact plan has no PA.

Which Aetna Ozempic policy does my plan use? A generic public page cannot tell you. Check the Ozempic entry in your member portal or drug list for PA, step-therapy, and quantity-limit markers. Ask Aetna or Caremark for the policy or criteria reference number used on your case.

What A1C do I need for Aetna to approve Ozempic? A history of 6.5% or higher is one way to document type 2 diabetes under 2439-C and 5694-D. A separate threshold of 7.5% appears in the 2439-C combination-therapy door. Those two numbers do different jobs.

Do I have to try metformin before Aetna covers Ozempic? Not as a universal rule in any of the three public documents we verified. In 2439-C, metformin is one of six doors. In 5694-D, a qualifying metformin fill is one way to pass the history screen and must be at least 10 days before the Ozempic claim. Your own plan can still add step therapy.

Can I submit the prior authorization myself? Aetna says you or your pharmacy can ask your doctor to start it. The doctor submits the clinical request because diagnosis, lab results, and records may be required. Your job is to confirm the record, get the case number, and follow the decision letter.

How long is an Aetna Ozempic approval good for? Twelve months under 2439-C and 36 months under 5694-D. 4525-H does not state an approval period because it is a quantity-limit document. Confirm the dates in your own approval notice.

Why did Aetna deny my Ozempic with no useful explanation? The public Indiana Caremark filing used one broad denial label across all reported denials: "does not meet clinical criteria." Ask which policy number and exact criterion were used. That answer determines whether you fix the record or appeal.

Does Aetna cover Ozempic for weight loss? The three public Ozempic policies we verified do not give a weight-loss-only door, and Ozempic is not FDA-approved for weight loss. Aetna's current Standard Plan lists both the Ozempic pen and Ozempic tablets under diabetes drugs, not antiobesity drugs. Your exact plan controls any exception right.

Are Ozempic tablets covered differently than the pen? Yes. 2439-C gives the pen an established-heart-disease door and a CKD door the tablet doesn't have, and gives the tablet a high-cardiovascular-risk door the pen doesn't have. Refill limits also differ: one pen per 21 days versus 30 tablets per 25 days in that policy.

Why does my pharmacy say it's too soon to refill? The public quantity policies use 21 days for a pen representing a 28-day fill and 25 days for 30 tablets representing a 30-day fill. That leaves processing room but does not guarantee payment on a specific date. Check the last paid claim, billed day supply, package size, and authorization dates.

Does Aetna Medicare cover Ozempic? Possibly through Part D for type 2 diabetes when it appears on your plan's drug list. The Medicare GLP-1 Bridge program does not cover Ozempic. Aetna states that directly on its current Medicare page.

What if my authorization expired? Aetna says your doctor needs to submit a new request if treatment should continue. Start before the expiration date when you can, because a refill may reject while the new request is unresolved.

Is Aetna Better Health the same as commercial Aetna? No. Aetna Better Health runs through state Medicaid programs, and each state sets its own drug list, criteria, forms, and submission routes. Use your state's current materials, not the commercial documents described on this page.

---

Before you go

If you take three things from this page:

1. Check your last 730 days of pharmacy claims under the same benefit. A true diabetes diagnosis code, a qualifying 30-day diabetes supply, a metformin fill at least 10 days before the claim, or another non-target diabetes drug may clear the 5694-D screen.
2. Find your door before your doctor writes anything. 2439-C has six, and metformin is only one. The CKD door for the Ozempic pen has no numeric eGFR threshold in the public text.
3. If you were denied, do not stop at the label. Ask for the policy number and exact failed criterion. In one Indiana all-drug dataset, only 10.1% of denials were appealed and 58.8% of filed appeals were approved.

You're not fighting a wall. You're fighting a form. Forms can be fixed.

---

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

---

Last verified: August 14, 2026 · The RX Index Research Team

This page explains insurance coverage rules. It is not medical advice. Coverage policies change — confirm details with your plan documents, your member portal, or the number on your ID card before making decisions.

---